Perry Calias, formerly of Shire Plc, has joined the Pharming Group NV as chief scientific officer with responsibility for the company’s enzyme replacement therapy programmes. He will be based in Boston, Massachusetts US. Dr Calias is a targeted therapy specialist with experience in research and development at Shire, BBB Technologies, EyeGate Pharmaceuticals, Eyetech Pharmaceuticals and Genzyme (now Sanofi).
He is listed as an inventor on over 30 patents or patent applications spanning 18 different patent families from mRNA therapeutics to combination anti-angiogenic therapies. He holds a PhD in bio-organic chemistry.
Pharming announced the appointment on 18 February 2015.
Copyright 2015 Evernow Publishing Ltd